DS-1093
/ Daiichi Sankyo
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
November 21, 2025
Discovery of DS79540454 via fragment-based drug discovery strategy: New scaffolds of hypoxia-inducible factor prolyl hydroxylase inhibitor.
(PubMed, Bioorg Med Chem Lett)
- "We discovered brand-new amino succinic acid scaffolds by combining the structural information on the crystal structure complexed with 6-acetamide nicotinic acid. DS79540454 exhibits high enzyme inhibitory activity equivalent to that of DS-1093a, which has advanced to clinical trials."
Journal • Hematological Disorders
July 18, 2024
Discovery of DS-1093a: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
(PubMed, Bioorg Med Chem Lett)
- "Furthermore, through the optimization of pyrimidine derivatives, we discovered DS-1093a, which has a wide safety margin with potent in vitro activity and an optimal pharmacokinetic profile. DS-1093a achieved an increase in hemoglobin levels in an adenine-induced rat model of chronic kidney disease after its continuous administration for 4 days."
Journal • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease
November 24, 2014
Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Daiichi Sankyo Inc.
New P1 trial • Biosimilar • Chronic Kidney Disease • Renal Disease
1 to 3
Of
3
Go to page
1